TY - JOUR
T1 - Weekly epirubicin plus lonidamine in advanced breast carcinoma
AU - Nisticò, Cecilia
AU - Garufi, Carlo
AU - Milella, Michele
AU - D'Ottavio, Anna Maria
AU - Vaccaro, Angela
AU - Fabi, Alessandra
AU - Terzoli, Edmondo
PY - 1999
Y1 - 1999
N2 - Lonidamine has been demonstrated to potentiate the cytotoxic activity of several antineoplastic drugs, for example anthracyclines. Moreover, epirubicin is considered one of the most active drugs in advanced breast cancer, although optimal dose and schedule remains to be defined. In the present study we have treated 51 patients with advanced breast cancer with a combination of lonidamine (450 mg/day orally from day 1 throughout treatment) and epirubicin (25 mg/m2 IV) administered according to a weekly schedule for 24 weeks. Objective responses were observed in 29 out of 51 patients (57%; CR 16%, PR 41%). Liver metastases responded in eight out of 12 evaluable patients (67%). Average response duration was 12.4 months and median overall survival was 23 months (range 1-90+). Toxicity was negligible. The combination of weekly epirubicin and lonidamine is feasible and active in advanced breast cancer patients.
AB - Lonidamine has been demonstrated to potentiate the cytotoxic activity of several antineoplastic drugs, for example anthracyclines. Moreover, epirubicin is considered one of the most active drugs in advanced breast cancer, although optimal dose and schedule remains to be defined. In the present study we have treated 51 patients with advanced breast cancer with a combination of lonidamine (450 mg/day orally from day 1 throughout treatment) and epirubicin (25 mg/m2 IV) administered according to a weekly schedule for 24 weeks. Objective responses were observed in 29 out of 51 patients (57%; CR 16%, PR 41%). Liver metastases responded in eight out of 12 evaluable patients (67%). Average response duration was 12.4 months and median overall survival was 23 months (range 1-90+). Toxicity was negligible. The combination of weekly epirubicin and lonidamine is feasible and active in advanced breast cancer patients.
KW - Advanced breast cancer
KW - Epirubicin
KW - Lonidamine
KW - Weekly schedule
UR - http://www.scopus.com/inward/record.url?scp=0032751627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032751627&partnerID=8YFLogxK
M3 - Article
C2 - 10573114
AN - SCOPUS:0032751627
VL - 56
SP - 233
EP - 237
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 3
ER -